On October 20, 2015, Valenta officially launched a new form of antiviral medicine for flu and ARVI in children aged over 7 years on the pharmaceutical market
Within the XIV Russian Congress “Innovative Technologies in Pediatrics and Children's Surgery”, Valenta organized a satellite scientific and practical symposium, where leading experts in the field of pediatrics presented actual statistics on flu and ARVI in children, and discussed the prospects of therapy of diseases in a certain age group and the results of a study of clinical effectiveness and safety of Ingavirin® application for children.
According to WHO, flu and ARVI make 60% of all children’s infectious pathology. Every 3rd-5th child gets sick with flu annually in the world. During the epidemiological season of 2014-2015, all age groups were involved, and children aged between 0 and 14 years made about 60%1. The following factors determine ARVI prevalence in children: high viruses diversity, variability, high contagiousness, low immunity, involvement of mucous of respiratory tract (upper and lower respiratory systems); status of lympho-pharynx ring and features of younger children’s organism, etc.
Immunization does not solve all epidemic problems connected with ARVD. They do not cover all ethiologic array of ARVI. Antiviral medicines – over 40 groups of medical products – make about 10%2 of prescriptions made by pediatricians at acute clinical conditions caused by respiratory viruses or for prevention of diseases during epidemic season.
N.A.Geppe, D.M.Sci., Professor, the Honored Doctor of the Russian Federation, Head of the Department of Children's Diseases, Director of Clinic at Sechenov First MSMU: : «Choice of chemotherapeutic methods of ARVI etiotropic therapy in children is rather limited. Some medicines are aimed only at certain flu viruses. Other are insufficiently studied from the point of view of their safety for younger children. Certain antiviral medicines induce the development of resistance, while other products feature side effects at systemic application. In this connection, the issue of development of effective, safe, compliant antiviral medicines featuring multi-range effect in treating children is of extreme urgency today.».
The results of a double blind randomized placebo-controlled multi-center study of clinical effectiveness and safety of Ingavirin® in a daily dose of 60 mg to treat children aged between 7 and 12 years for flu and ARVI were presented within the symposium. Administering the medicine during the first 36 hours of the clinical course induced an authentic decrease of the period of fever (42.0 hours against 54.5 hours for placebo group), promoted facilitation of the course of disease and 8.7 times reduced the risk of complications in comparison with placebo. The medicine showed a favorable safety profile, while no serious undesirable phenomena were registered in connection with taking the medicine3.
A.Y.Egorov, D.B.Sci., Professor, University of Natural Resources and Natural Sciences, Vienna, Austria: «Ingavirin is particularly distinguished among domestic antiviral medicines by its mechanism of action, clinical effectiveness, safety and multi-range effect. On the basis of our own large-scale experimental clinical data, application of the medicine in flu/ARVI therapy for children aged over 7 years is grounded etiologically and pathogenetically».
Alexander Machin, Marketing and Sales Manager, OAO “Valenta Pharm”: «Today we officially launch on the Russian market a new form of Ingavirin® to treat flu and ARVI in children aged over 7 years. The reports presented at our symposium emphasized high urgency of duly treatment of acute respiratory viral diseases in children. Possessing significant experience in creation of medicines we have an opportunity to launch on the market medical products complying with the priority medical requirements of the Russian patients of various age groups».
1 State report “About the situation in the field of sanitary and epidemiologic safety and wellbeing of population in the Russian Federation in 2014”
2 According to studies made by Synovate Comcon, 2014
3 N.A.Geppe, D.V.Reihart, V.E.Nebolsin, A.V.Golubev, V.S.Arnautov. “Innovations in Flu and Other ARVI Therapies in Children Aged between 7 and 17 Years”, “District Pediatrician”, No.4, 2015, p.15-17.